Metabolic syndrome following liver transplantation in nonalcoholic steatohepatitis.

Metabolic syndrome is a major clinical disorder involving metabolic dysregulation characterized clinically with features of central obesity, insulin resistance (IR), type 2 diabetes, hypertension, and dyslipidemia. Metabolic syndrome is strongly associated with the rising prevalence nonalcoholic steatohepatitis, a leading indication for orthotopic liver transplantation in the Western world. The presence or recurrence of metabolic syndrome following liver transplantation can contribute to the development and recurrence of nonalcoholic fatty liver disease (NAFLD) in the liver allograft. In this review, we discuss the endogenous and exogenous drivers of post-transplant metabolic syndrome, role of chronic immunosuppression, and the prevalence and clinical significant of post-transplant metabolic syndrome on nonalcoholic steatohepatitis.
Competing Interests: Conflicts of Interest: The series “Liver Transplantation in NASH and ALD” was commissioned by the editorial office without any funding or sponsorship. Dr. Abdelmalek receives grant funding paid to her institution for research in NAFLD/NASH from Intercept, Allergan, Genfit, Bristol-Myers Squibb, NGM Bio, Tiawan J, Madrigal, Gilead, Novo-Nordisk, Poxel, Durect, Inventiva, Viking, Galactin. Dr. Abdelmalek is a scientific advisor for Bristol-Myers Squibb, NGM Bio, Tiawan J, Novo-Nordisk, Inventiva and serves on the speaker’s bureau for Alexion and Intercept. Dr. Spiritos has no conflicts of interest to declare.
(2021 Translational Gastroenterology and Hepatology. All rights reserved.)